Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ralph Lauren Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Ralph Lauren Corp trades at $398 (market cap $23.70B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.94% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RL | |
|---|---|---|
Market Cap | $29.60B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $414.25 |
52-Week Low | $205.48 | $285.35 |
Enterprise Value | $27.56B | $24.76B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Ralph Lauren (RL) trades at $396.34, down 2.59% on the day, yet maintains strong fundamentals with consistent earnings beats and robust profitability. The stock exhibits a bullish technical trend, supported by positive analyst sentiment and a consensus price target of $456.50. Recent quarters show revenue growth and margin expansion, with Q1 2027 results exceeding expectations, reinforcing the company's brand resilience and strategic execution.
The outlook for RL remains favorable, driven by earnings momentum and global demand, though risks include consumer spending volatility and competitive pressures. With 66% of analysts rating it a Buy and institutional confidence high, the stock presents a growth opportunity, but investors should monitor macroeconomic headwinds that could impact discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
